Patent ID: 8003081

Claim:
A method for improvement of tolerance for an aerosolized primary therapeutically effective agent delivered to lungs of a patient in need thereof with an inhalable dry powder, comprising steps: a) preparing an inhalable dry powder consisting essentially of about 10 mg, 40 mg or 100 mg of lidocaine or a lidocaine-like acetanilide and benzamide compound and an excipient selected from the group consisting of lactose, lysine and leucine; wherein said dry powder have a mass median aerodynamic diameter between about 1 μm and about 10 μm with a geometric standard deviation lower than 1.7 b) selecting a dry powder or meter dose inhaler able to generate aerosol of particle sizes between 3.5 and 10 μm; c) nebulizing said inhalable dry powder into an aerosol having a mass median aerodynamic diameter of particles between about 4 μm and about 5 μm with a geometric standard deviation lower than 1.7; and d) administering said aerosol to said patient immediately before or within 30 minutes before administering said aerosolized primary therapeutically effective agent selected from the group consisting of α-proteinase-inhibitor, amikacin, carbenicillin, ceftazidim, colistin, gentamycin, imipenem, ticarcillin, penicillin, tobramycin, vancomycin, aztreonam, fosfomycin, rifampicin, ciprofloxacin, quinolone, glutathion, pentamidine, nifedipine, verapamil, amiloride, benzamil, furosemide, piretanid, torasemid, heparin, cyclosporine, prednisone, methotrexate, azathoprine, mycophenoline, sirolimus, tacrolimus, mofetil, α-interferone, β-interferone, γ-interferone, interleukin 2, adrenaline, retinoic acid, amphotericin B, beclomethasone, cefoperazone, ciproflaxine, fentanyl, fusafungin, DNA, magnesium sulfate, dextrane, dornase α, hypertonic saline, mannitol. N-acetylcystein, nitroglycerine, nitroprusside sodium, morphine, prostaglandin, indomethacin, budesonide, dexamethasone, aminophylline, ribavirine and human growth factor.